Hypersensitivity News and Research RSS Feed - Hypersensitivity News and Research

Hypersensitivity is an exaggerated response by the immune system to a drug or other substance.
Researchers propose new explanation for symptoms of fragile X syndrome

Researchers propose new explanation for symptoms of fragile X syndrome

Until recently, scientists thought they understood one of the underlying causes of fragile X syndrome, the most common inherited cause of intellectual disability in the United States. [More]
Research provides insight into link between chronic pain and anxiety

Research provides insight into link between chronic pain and anxiety

New research provides insight into a long-observed, but little-understood connection between chronic pain and anxiety and offers a potential target for treatment. [More]
New research aims to understand, manage contact lens discomfort

New research aims to understand, manage contact lens discomfort

Do you have dry eyes or other symptoms related to wearing contact lenses? If so you're not alone—up to 50 percent of contact lens wearers experience dryness or discomfort at least occasionally. [More]
Preclinical data on Selecta’s novel immune tolerance platform published in Nature Nanotechnology

Preclinical data on Selecta’s novel immune tolerance platform published in Nature Nanotechnology

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies for rare and serious diseases, announced today that Nature Nanotechnology has published an article that presents preclinical results from Selecta’s research which demonstrate the broad potential applicability of Selecta’s novel immune tolerance platform. [More]
FDA approves new injection to improve blood sugar levels in adults with type 2 diabetes

FDA approves new injection to improve blood sugar levels in adults with type 2 diabetes

The U.S. Food and Drug Administration approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes. [More]
New non-drug approach may help manage pain in individuals receiving addiction treatment

New non-drug approach may help manage pain in individuals receiving addiction treatment

It's a Catch-22 with potentially deadly consequences: People trying to overcome addiction can't get treatment for their pain, because the most powerful pain medicines also carry an addiction risk. [More]
Japanese researchers suggest link between stimulus response and consciousness

Japanese researchers suggest link between stimulus response and consciousness

Japanese researchers centered at Nagoya University reveal a role for orexin neurons of the hypothalamus when mice respond to painful stimuli, and suggest a link between stimulus response and consciousness. [More]
Transplant drug rapamycin may reduce nerve damage, neuropathic pain after spinal cord injury

Transplant drug rapamycin may reduce nerve damage, neuropathic pain after spinal cord injury

New research in mice indicates that a drug commonly used to suppress the immune system in recipients of organ transplants may also reduce tissue damage and neuropathic pain after spinal cord injury. The findings are published in the Journal of Orthopaedic Research. [More]
Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Mallinckrodt plc, a leading global specialty biopharmaceutical company, today announced new retrospective health economic data on H.P. Acthar® Gel (repository corticotropin injection; RCI), which may be an option for the management of multiple sclerosis (MS) relapses. [More]
FDA approves Absorb GT1 BVS to treat coronary artery disease

FDA approves Absorb GT1 BVS to treat coronary artery disease

The U.S. Food and Drug Administration today approved the first fully absorbable stent to treat coronary artery disease. [More]
TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

Merck, a leading science and technology company, will present data at the ESMO 18th World Congress on Gastrointestinal Cancer from the pivotal Phase III TAILOR study in patients from China, the first prospective trial to evaluate an anti-EGFR antibody in the first-line therapy of patients with RAS wild-type metastatic colorectal cancer (mCRC). [More]
IU researchers identify suite of genes that play role in nerve sensitivity

IU researchers identify suite of genes that play role in nerve sensitivity

Indiana University researchers have that found a suite of genes in both fruit flies and humans -- including one dubbed "smoke alarm" -- plays a role in nerve sensitivity. The study could help lead to new drug targets in pain management. [More]
New study identifies 40 genes susceptible to migraine

New study identifies 40 genes susceptible to migraine

Migraine is one of the most common neurological disorders and it affects 1 out of 7 people in the world. Painful and incapacitating, it has multi-factor origins, with the participation of environmental triggering factors and several altered genes in each individual. [More]
Zinbryta gets FDA approval for treating adults with relapsing forms of MS

Zinbryta gets FDA approval for treating adults with relapsing forms of MS

The U.S. Food and Drug Administration today approved Zinbryta (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis (MS). Zinbryta is a long-acting injection that is self- administered by the patient monthly. [More]
Early-life stress may lead to functional dyspepsia in adulthood

Early-life stress may lead to functional dyspepsia in adulthood

Traumatic events early in life can increase levels of norepinephrine—the primary hormone responsible for preparing the body to react to stressful situations—in the gut, increasing the risk of developing chronic indigestion and anxiety during adulthood, a new study in American Journal of Physiology—Gastrointestinal and Liver Physiology reports. [More]
Researchers investigate effects of non-allergenic components of pollen on allergy sufferers

Researchers investigate effects of non-allergenic components of pollen on allergy sufferers

Up to now, research into pollen allergies has largely focused on allergens - those components of pollen that trigger hypersensitivity reactions. When it comes into contact with the nasal mucous membrane, however, pollen releases a host of other substances in addition to allergens. [More]
Gene therapy could be potential treatment for neuropathic pain in cancer patients

Gene therapy could be potential treatment for neuropathic pain in cancer patients

A study providing new information about neuropathic pain afflicting some 90 percent of cancer patients who have had nerve damage caused by tumors, surgery, chemotherapy or radiation indicates gene therapy as a possible treatment. [More]
Common misconception about penicillin allergies

Common misconception about penicillin allergies

It's time for your primary care check-up, and the doctor asks you to list any known drug allergies. "Penicillin," you say immediately, although you can't remember actually taking the drug or having a reaction to it—it was your parents who said so. According to a Texas A&M Health Science Center allergist, many people who believe they're allergic to this antibiotic may not actually be allergic at all. [More]
Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress. [More]
MGH-led study confirms safety of allergy immunotherapy

MGH-led study confirms safety of allergy immunotherapy

A team of Massachusetts General Hospital investigators has found no evidence of infections related to administration of allergy immunotherapy, the common practice of injecting minimal quantities of allergens beneath the skin to reduce the allergic response. [More]
Advertisement
Advertisement